| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Oncology | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Oncology | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Oncology |
Recent Updates
Recently added Catalysts
Eikon Therapeutics, Inc.$10.58
-0.64 (-5.7%)
C 55Pipeline Score Fair Value Biotech · Clinical
Market Cap
590.65 M
EPS
-
P/E Ratio
-
Value Trade
3.30 M
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
70.05 M
Operating CF
-89.80 M
Total Assets
850.83 M
Total Liabilities
300.15 M
Equity
550.67 M
D/E Ratio
12,345
-16.08 %
Week
-8.7 %
1 Month
-31.34 %
3 Month
-36.01 %
6 Month
-36.01 %
5 Year
-36.01 %
All Time
Cash Data
Cash Position
512.18 M
Monthly Burn
29.93 M
Runway
15.1 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
281.98 K
52 Week Range
7.90 - 17.40
% held by Insiders
53.18 %
% held by Institutions
37.76 %
Enterprise Value
332.90 M
Total Shares
54.17 M
Short %
17.41 %
Float Shares
26.60 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C55
Pipeline Score $830M
Pipeline ValueFair Value
Valuation Signal7
Drugs Scored1.4x
rNPV / MCap Top 83%
Micro Cap (rank 156 of 912)
Percentile RankEikon Therapeutics, Inc. carries a moderate pipeline score (55/100), with $2.9B risk-adjusted pipeline value, led by IMP1734 in Advanced Solid Tumor (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IMP1734 Small molecule | Advanced Solid Tumor | Phase 1 | NCT06253130 | 5% | $1.6B | RECRUITING | 156 | VERY_FAST | D (33) | Dec 1, 2027 | LOW_RISK | LOW Jun 16, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
EIK1001 | stage 4 NSCLC | Phase 2 | 2026-05-30 | 72 participants with previously untreated stage 4 NSCLC received intravenous EIK1001 QW combined with standard of care pembrolizumab plus chemotherapy Q3W. Read More | Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology Read More | |
EIK1001 | stage 4 NSCLC | Phase 2 | 2026-05-30 | 72 participants with previously untreated stage 4 NSCLC received intravenous EIK1001 QW combined with standard of care pembrolizumab plus chemotherapy Q3W. Read More | Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology Read More | |
EIK1001 | stage 4 NSCLC | Phase 2 | 2026-05-30 | 72 participants with previously untreated stage 4 NSCLC received intravenous EIK1001 QW combined with standard of care pembrolizumab plus chemotherapy Q3W. Read More | Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in EIKN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
EIKN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
EIKN▲ +16.2%on this news· ran to +29% by day 1
Eikon Therapeutics to Join the Russell 3000® Index
Eikon Therapeutics, a late-stage clinical biopharmaceutical company, announced its inclusion in the Russell 3000 Index, effective June 26, 2026. This addition highlights Eikon's growth and commitment to developing innovative medicines for serious medical needs, particularly in oncology. The Russell 3000 Index represents a significant portion of the US equity market, providing a benchmark for investors.
Read more →EIKNEikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors
Eikon Therapeutics has appointed Ma. Fatima D. Francisco as an independent director on its Board, effective June 15, 2026. Francisco, who has a notable background in leadership from Procter & Gamble, will also serve on the Compensation Committee. Her expertise is expected to enhance Eikon's efforts in developing innovative medicines for serious unmet medical needs.
Read more →EIKNQ2 Company Update June 2026 Disclaimer Any statements made in this presentation that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and shou
Eikon's Q2 Company Update outlines the progress of its clinical pipeline and highlights upcoming milestones for 2026. The FDA has sanctioned the transition to a Phase 2/3 registrational trial, with EIK1001 demonstrating efficacy in preliminary trials. However, the company is facing significant net losses and requires additional funding to support continued operations. Risks also include potential development failures and legal complications that could impact their future prospects.
Read more →EIKNEfficacy, safety and cytokine profiling with addition of the toll-like receptor (TLR) 7/8 dual agonist EIK1001 to Standard of Care First-Line Therapy: the Phase 2 TeLuRide-005 trial in Stage 4 Non-Small Cell Lung Cancer – Poster Presentation, ASCO 2026
The Phase 2 TeLuRide-005 trial evaluates the efficacy and safety of EIK1001, a TLR 7/8 dual agonist, when added to standard first-line therapy for Stage 4 Non-Small Cell Lung Cancer. The results were presented at ASCO 2026, highlighting promising data that could impact treatment protocols.
Read more →EIKNAdaptive Phase 2/3 Study of EIK1001, a TLR7/8 Dual Agonist, in Combination with Pembrolizumab, as First-Line Therapy in Participants with Advanced Melanoma (TeLuRide-006) – Poster Presentation, ASCO 2026
The article discusses the Adaptive Phase 2/3 study of EIK1001, a TLR7/8 dual agonist, in combination with Pembrolizumab for treating advanced melanoma. This study, known as TeLuRide-006, is set to be presented at ASCO 2026. The research aims to evaluate the effectiveness of this combination therapy as a first-line treatment option.
Read more →EIKNA Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008) – Poster Presentation, ASCO 2026
The article discusses a Phase 2/3 study of EIK1001 combined with pembrolizumab and chemotherapy for treating Stage 4 non-small cell lung cancer. This study, referred to as TeLuRide-008, will be presented as a poster at ASCO 2026. The research aims to evaluate the effectiveness of this combination therapy in improving patient outcomes.
Read more →EIKNA Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors, Including Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors – Poster Presentation, ASCO 2026
The article discusses a Phase 1/2 study of EIK1005, both as a standalone treatment and in combination with Pembrolizumab, targeting advanced solid tumors. The study focuses on patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) tumors. The findings were presented at ASCO 2026, highlighting the potential of EIK1005 in oncology.
Read more →EIKNEIK1003, a PARP1-selective inhibitor, in combination with paclitaxel (PTX): Initial combination and updated monotherapy results from a Phase 1/2 study EIK1003-001 in advanced solid tumors – Poster Presentation, ASCO 2026
The article discusses the initial combination and updated monotherapy results of EIK1003, a PARP1-selective inhibitor, in a Phase 1/2 study (EIK1003-001) for advanced solid tumors. The findings were presented at ASCO 2026, highlighting the potential effectiveness of EIK1003 when used alongside paclitaxel. This research could pave the way for new treatment options in oncology.
Read more →EIKNEikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology
Eikon Therapeutics presented updated data on its clinical-stage programs at the 2026 ASCO Annual Meeting. The Phase 2 trial of EIK1001 in stage 4 NSCLC showed promising response rates and tolerability. Additionally, EIK1003 demonstrated safety and efficacy as a monotherapy and in combination with paclitaxel for advanced solid tumors, reinforcing the potential of Eikon's innovative therapies.
Read more →EIKNEikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology
Eikon Therapeutics announced the acceptance of six abstracts for presentation at the 2026 ASCO Annual Meeting. These abstracts showcase clinical progress in their oncology pipeline, including trials for EIK1001, EIK1003, and EIK1005. The presentations will highlight both monotherapy and combination strategies aimed at optimizing treatment for advanced cancers.
Read more →EIKNEikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates
Eikon Therapeutics reported its first quarter 2026 financial results, highlighting a strong cash position of $596 million and continued progress in its oncology pipeline. The company focuses on three key programs: EIK1001, EIK1003, and EIK1005, with significant data to be presented at the upcoming ASCO annual meeting. Despite a net loss of $83 million, Eikon remains optimistic about its clinical advancements and financial outlook.
Read more →EIKNRapid Optimization Enabled by Single-Molecule Tracking: Discovery of a Potent RUVBL1/2 Inhibitor to Evaluate the Targeting of MYC-Driven Cancers
The article discusses the discovery of a potent RUVBL1/2 inhibitor through a Single-Molecule Tracking (SMT) approach, which enhances drug discovery by providing robust potency measurements. This inhibitor shows improved efficacy in a MYC-dependent Burkitt lymphoma xenograft model, indicating its potential in targeting MYC-driven cancers. The study highlights SMT's role in optimizing drug discovery campaigns.
Read more →EIKNEikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates
Eikon Therapeutics reported its fourth quarter and full year 2025 financial results, highlighting a successful IPO that raised $381 million. The company completed enrollment in the Phase 2 TeLuRide-005 trial for EIK1001 in lung cancer. Despite significant net losses and rising expenses, Eikon is advancing its clinical programs and expects to fund operations into 2027.
Read more →EIKNEikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates Closed upsized initial public offering in February 2026, raising $381 million in gross proceeds
Eikon Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting a successful $381 million IPO. The company reported significant progress in its clinical programs, particularly with EIK1001 and next-generation PARP inhibitors. Despite these advancements, Eikon faces considerable challenges, including substantial net losses and increased operational expenses. The firm is optimistic about its future, leveraging its strengthened financial position to pursue further development of its innovative therapies.
Read more →EIKNEikon Therapeutics Announces Pricing of Upsized Initial Public Offering
Eikon Therapeutics has announced the pricing of its upsized initial public offering, offering 21,177,600 shares at $18.00 each. The offering is expected to generate approximately $381 million in gross proceeds. Eikon's common stock will begin trading on the Nasdaq under the ticker symbol 'EIKN' on February 5, 2026. The offering is subject to customary closing conditions.
Read more →EIKNEikon Therapeutics Announces the Election of David W. Meline to its Board of Directors
Eikon Therapeutics has elected David W. Meline as an independent director, effective November 23, 2025. Meline, former CFO at Moderna and Amgen, brings significant financial and operational expertise to the board. His appointment is expected to enhance Eikon's strategic growth as the company advances its drug discovery initiatives.
Read more →EIKNEikon Therapeutics to Present New Phase 2 Data on EIK1001 in First-Line Non-Small Cell Lung Cancer at ESMO 2025
Eikon Therapeutics will present new Phase 2 data on EIK1001 at the ESMO Congress 2025. The study evaluates EIK1001, a TLR7/8 co-agonist, in combination with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer. The results aim to demonstrate improved patient outcomes and support the progression to a Phase 2/3 trial.
Read more →EIKNEikon Therapeutics to Share Clinical Data and Program Updates at the 2025 ASCO Annual meeting
Eikon Therapeutics will present new clinical data and program updates at the ASCO Annual Meeting from May 30 to June 3, 2025. The presentations will include safety and efficacy data from their selective PARP1 inhibitor EIK1003 and updates on their other oncology programs. Eikon has also entered a collaboration with Merck for a clinical trial involving EIK1001.
Read more →EIKNEikon Therapeutics Secures $350.7 Million Series D to Advance Clinical-Stage Programs and Future Pipeline
Eikon Therapeutics has announced the closing of a $350.7 million Series D financing round, led by existing investors and including new participants. This funding will support the advancement of its clinical-stage programs, particularly EIK1001 for advanced melanoma, and other promising therapies in development. The company aims to leverage its innovative drug discovery technologies to accelerate the development of new medicines.
Read more →EIKNOblique line scan illumination enables expansive, accurate and sensitive single-protein measurements in solution and in living cells
The article discusses a new technique called oblique line scan illumination, which allows for expansive, accurate, and sensitive measurements of single proteins both in solution and within living cells. This advancement could significantly enhance the study of protein dynamics and interactions in biological systems.
Read more →EIKNEikon Therapeutics Announces Nature Methods Publication Highlighting its Pioneering Oblique Line Scan Technology
Eikon Therapeutics has published a paper in Nature Methods showcasing its innovative Oblique Line Scan (OLS) technology, which enhances its Single Molecule Tracking (SMT) platform. This technology allows for high-throughput analysis of protein dynamics, significantly improving the understanding of cellular processes and drug interactions. Eikon's advancements aim to accelerate drug discovery and provide deeper insights into fundamental biology.
Read more →EIKNEikon Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Eikon Therapeutics will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025. CEO Roger M. Perlmutter will discuss recent clinical development progress and advancements in research programs. This presentation underscores the company's commitment to accelerating drug discovery and development.
Read more →EIKNEikon Therapeutics Announces Appointment of Michael Klobuchar as Chief Operating Officer
Eikon Therapeutics has appointed Michael A. Klobuchar as Chief Operating Officer. Klobuchar, previously at Merck, will oversee corporate infrastructure and strategic alignment as Eikon enters a growth phase. His extensive experience in various sectors will support the company's mission to advance drug discovery and development. Eikon aims to leverage innovative technologies for therapeutic advancements.
Read more →EIKNDiscovery and Development of EIK1003, a Potent and Selective PARP1 Inhibitor | EORTC 2024 Poster Presentation
The article discusses the discovery and development of EIK1003, a potent and selective PARP1 inhibitor. This compound is set to be presented at the EORTC 2024 conference, indicating a significant advancement in cancer treatment research. The focus on PARP1 inhibition suggests promising therapeutic applications.
Read more →EIKNEikon Therapeutics Management to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Eikon Therapeutics will present a business update at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024. CEO Roger M. Perlmutter and CFO Alfred Bowie will discuss recent advancements in the company's pipeline and clinical development programs. The presentation can be accessed by interested parties via an audio recording.
Read more →EIKNSPT-derived estrogen receptor dynamics predicts therapeutic effects in clinical compounds | CSHL Poster Presentation
The article discusses a poster presentation at CSHL focusing on SPT-derived estrogen receptor dynamics. This research aims to predict the therapeutic effects of clinical compounds, potentially influencing future treatment approaches. The findings could contribute to a better understanding of estrogen receptors in therapeutic contexts.
Read more →EIKNWRN inhibition leads to its chromatin-associated degradation via the PIAS4-RNF4-p97/VCP axis
The article discusses a study revealing that the inhibition of WRN leads to its degradation associated with chromatin through the PIAS4-RNF4-p97/VCP axis. This discovery suggests potential therapeutic applications, particularly in cancer treatment. The identification of this novel degradation pathway could pave the way for innovative strategies in targeting WRN.
Read more →EIKNEikon Therapeutics to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
Eikon Therapeutics will present at the 45th Annual Goldman Sachs Global Healthcare Conference on June 12, 2024. CEO Roger M. Perlmutter and CFO Alfred Bowie will discuss the company's pipeline and clinical development progress. The presentation aims to showcase Eikon's innovative approaches in drug discovery.
Read more →EIKNOptimized Properties and Synthesis of Photoactivatable Diazoketorhodamines Facilitate and Enhance High-Throughput Single-Molecule Tracking
The article discusses advancements in the properties and synthesis of photoactivatable diazoketorhodamines. These improvements are designed to enhance high-throughput single-molecule tracking, potentially benefiting various research applications. The optimized compounds promise to facilitate more efficient tracking in molecular studies.
Read more →EIKNEikon Therapeutics Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
Eikon Therapeutics announced multiple abstracts for the 2024 ASCO Annual Meeting, showcasing its clinical-stage programs EIK1001 and EIK1003. An oral presentation will highlight the safety and preliminary efficacy of EIK1001 in combination with pembrolizumab, while three poster presentations will cover EIK1001's combinations with pembrolizumab and atezolizumab, as well as a Phase 1 study of EIK1003. The event will take place in Chicago from May 31 to June 4, 2024.
Read more →EIKNA high-throughput platform for single-molecule tracking identifies drug interaction and cellular mechanisms
A new high-throughput platform has been developed for single-molecule tracking, which aims to identify drug interactions and elucidate cellular mechanisms. This innovative technology could significantly advance research in drug development and cellular biology. The platform promises to provide deeper insights into how drugs interact at the molecular level.
Read more →EIKNHigh Throughput SMT Provides Insight Across Diverse Areas of Cell Biology | CSHL 2024 Poster Presentation
The article announces a poster presentation at CSHL 2024, highlighting the capabilities of High Throughput SMT in providing insights across various fields of cell biology. This innovative approach is expected to contribute significantly to research and understanding in the area. The event aims to showcase advancements in the technology and its applications.
Read more →EIKNEikon Therapeutics Presents Pharmacokinetic/Biomarker Analysis of the Toll-Like Receptor 7 and 8 (TLR7/8) Agonist EIK1001 at the Annual Meeting of the American Association for Cancer Research
Eikon Therapeutics presented findings on EIK1001's pharmacokinetics and biomarker data at the AACR Annual Meeting. The analysis from two Phase 1 trials indicated a linear and dose-proportional PK profile, with dose-dependent increases in IP-10 and IFNg, aligning with the drug's mechanism of action. These results support future trial designs and dose optimization.
Read more →EIKNEikon Therapeutics to Provide Corporate Updates at the 42nd Annual J.P. Morgan Healthcare Conference
Eikon Therapeutics announced significant updates at the 42nd Annual J.P. Morgan Healthcare Conference, including the advancement of EIK1001 into Phase 2 trials for lung cancer and the enrollment of patients in a Phase 1 trial for EIK1003, a selective PARP1 inhibitor. The company also initiated IND-enabling studies for a brain-penetrant PARP1 inhibitor and established a new business unit focused on proprietary technology. Eikon anticipates identifying additional clinical candidates in early 2024.
Read more →EIKNExclusive: Roger Perlmutter on the biggest problem in Big Pharma, leaving Merck, and building Eikon
Roger Perlmutter, former head of R&D at Merck, has transitioned to CEO of Eikon Therapeutics shortly after leaving Merck. At Eikon, he is focused on building advanced microscopes and developing new drugs, positioning the company as a significant player in the biopharma industry.
Read more →EIKNRoger Perlmutter lights up the biological dark, building a new pharma force in Eikon and its superpowered microscopes
Eikon aims to revolutionize drug discovery by using advanced microscopy to observe cellular mechanics at the protein level. This innovative approach seeks to identify and tackle challenging drug targets in real-time, leveraging Nobel Prize-winning technology on an industrial scale. The company's efforts could significantly impact the biopharmaceutical landscape.
Read more →EIKNEikon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Eikon Therapeutics, a biotechnology company, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024. CEO Roger M. Perlmutter will update attendees on the company's pipeline and clinical development progress. Eikon focuses on enhancing drug discovery through advanced engineering and proprietary technologies.
Read more →EIKNEikon Therapeutics Announces the Election of Robert L. Huffines to its Board of Directors
Eikon Therapeutics has appointed Robert L. Huffines as an independent director, effective December 1, 2023. Huffines, who has over 30 years of experience in investment banking at J.P. Morgan Chase, is expected to provide valuable insights to enhance Eikon's growth. His expertise in life sciences and commitment to bioethics will support the company's mission to develop transformative medicines.
Read more →EIKNEikon Therapeutics Announces Business Update Highlighting Pipeline and Clinical Development Progress
Eikon Therapeutics has made significant strides in its clinical development pipeline, including the IND clearance for its lead selective PARP1 inhibitor, IMP1734, and the integration of TLR 7 and 8 agonist programs. The company plans to initiate Phase 1 studies for these assets in the fourth quarter. Additionally, Eikon is expanding its preclinical pipeline with various innovative therapeutic candidates targeting different pathways.
Read more →Competitive Position
How EIKN ranks across every disease it competes inCompetitive Position is a premium feature
See how EIKN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial